ambroxol has been researched along with Idiopathic Parkinson Disease in 16 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Excerpt | Relevance | Reference |
---|---|---|
"The ambroxol therapy was well tolerated, with no serious adverse events." | 6.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 6.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
"Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 6.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
"Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 5.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
"Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 5.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
"Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 5.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
" The literature review of the usage of ambroxol acting as a pharmacological chaperone for beta-glucocerebrosidase in Gaucher disease and Parkinson’s disease associated with GBA variants has been reviewed." | 5.22 | Pharmacological chaperone therapy for the treatment of inborn errors of metabolism ( Jezela-Stanek, A; Lipiński, P; Tylki-Szymańska, A, 2022) |
"Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease α-synuclein and phosphorylated α-synuclein protein levels." | 3.83 | Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. ( Bezard, E; Daly, L; Migdalska-Richards, A; Schapira, AH, 2016) |
"The ambroxol therapy was well tolerated, with no serious adverse events." | 2.94 | Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. ( Cable, S; Campbell, P; D'Souza, G; Elflein, J; Foltynie, T; Hällqvist, J; Hehir, J; Heywood, WE; Hosking, J; Khengar, R; Lee, K; Libri, V; Limousin, P; Mills, K; Mullin, S; Schapira, AHV; Smith, L; Streeter, A; Toffoli, M; Woodgate, P; Zetterberg, H, 2020) |
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD." | 2.90 | Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019) |
"Both patients with non-neuronopathic Gaucher disease (GD) and heterozygous GBA mutation carrier are at increased risk for Parkinson disease (PD)." | 2.58 | Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. ( Arkadir, D; Dinur, T; Ilan, Y; Ishay, Y; Szer, J; Zimran, A, 2018) |
"Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine." | 1.62 | Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. ( Al-Hertani, W; Becker-Cohen, M; Castillo-Garcia, D; Ceron-Rodriguez, M; Chan, A; Dinur, T; Fiumara, A; Istaiti, M; Kiec-Wilk, B; Lee, BH; Ramaswami, U; Revel-Vilk, S; Rodic, P; Rubio, B; Tincheva, RS; Yang, CF; Zimran, A, 2021) |
"Ambroxol treatment significantly reduced HexSph concentration in GD (by 2." | 1.62 | Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. ( Baydakova, GV; Bezrukikh, VA; Bogdanova, DA; Bolshakova, OI; Cheblokov, AA; Emelyanov, AK; Kopytova, AE; Miliukhina, IV; Nikolaev, MA; Pchelina, SN; Rychkov, GN; Salogub, GN; Sarantseva, SV; Senkevich, KA; Usenko, TC; Zakharova, EY, 2021) |
"Treatment with ambroxol hydrochloride increased glucosylceramidase activity in fibroblasts from healthy controls, Gaucher disease and heterozygous glucocerebrosidase mutation carriers with and without Parkinson's disease." | 1.40 | Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. ( Abramov, AY; Chau, KY; Cooper, JM; Foltynie, T; Gegg, M; Hughes, D; Magalhaes, J; McNeill, A; Mehta, A; Schapira, AH; Shen, C, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 9 (56.25) | 24.3611 |
2020's | 7 (43.75) | 2.80 |
Authors | Studies |
---|---|
Yang, SY | 2 |
Taanman, JW | 2 |
Gegg, M | 2 |
Schapira, AHV | 3 |
Tripathi, P | 1 |
Ganeshpurkar, A | 1 |
Singh, SK | 1 |
Krishnamurthy, S | 1 |
Lipiński, P | 1 |
Jezela-Stanek, A | 1 |
Tylki-Szymańska, A | 1 |
Mullin, S | 1 |
Smith, L | 1 |
Lee, K | 1 |
D'Souza, G | 1 |
Woodgate, P | 1 |
Elflein, J | 1 |
Hällqvist, J | 1 |
Toffoli, M | 1 |
Streeter, A | 1 |
Hosking, J | 1 |
Heywood, WE | 1 |
Khengar, R | 1 |
Campbell, P | 1 |
Hehir, J | 1 |
Cable, S | 1 |
Mills, K | 1 |
Zetterberg, H | 1 |
Limousin, P | 1 |
Libri, V | 1 |
Foltynie, T | 2 |
Schneider, SA | 1 |
Alcalay, RN | 1 |
Istaiti, M | 1 |
Revel-Vilk, S | 1 |
Becker-Cohen, M | 1 |
Dinur, T | 2 |
Ramaswami, U | 1 |
Castillo-Garcia, D | 1 |
Ceron-Rodriguez, M | 1 |
Chan, A | 1 |
Rodic, P | 1 |
Tincheva, RS | 1 |
Al-Hertani, W | 1 |
Lee, BH | 1 |
Yang, CF | 1 |
Kiec-Wilk, B | 1 |
Fiumara, A | 1 |
Rubio, B | 1 |
Zimran, A | 2 |
Kopytova, AE | 1 |
Rychkov, GN | 1 |
Nikolaev, MA | 1 |
Baydakova, GV | 1 |
Cheblokov, AA | 1 |
Senkevich, KA | 1 |
Bogdanova, DA | 1 |
Bolshakova, OI | 1 |
Miliukhina, IV | 1 |
Bezrukikh, VA | 1 |
Salogub, GN | 1 |
Sarantseva, SV | 1 |
Usenko, TC | 1 |
Zakharova, EY | 1 |
Emelyanov, AK | 1 |
Pchelina, SN | 1 |
Silveira, CRA | 1 |
MacKinley, J | 1 |
Coleman, K | 1 |
Li, Z | 1 |
Finger, E | 1 |
Bartha, R | 1 |
Morrow, SA | 1 |
Wells, J | 1 |
Borrie, M | 1 |
Tirona, RG | 1 |
Rupar, CA | 1 |
Zou, G | 1 |
Hegele, RA | 1 |
Mahuran, D | 1 |
MacDonald, P | 1 |
Jenkins, ME | 1 |
Jog, M | 1 |
Pasternak, SH | 1 |
McNeill, A | 1 |
Magalhaes, J | 1 |
Shen, C | 1 |
Chau, KY | 3 |
Hughes, D | 1 |
Mehta, A | 1 |
Cooper, JM | 1 |
Abramov, AY | 1 |
Schapira, AH | 3 |
Albin, RL | 1 |
Dauer, WT | 1 |
Ambrosi, G | 1 |
Ghezzi, C | 1 |
Zangaglia, R | 1 |
Levandis, G | 1 |
Pacchetti, C | 1 |
Blandini, F | 1 |
Maor, G | 1 |
Cabasso, O | 1 |
Krivoruk, O | 1 |
Rodriguez, J | 1 |
Steller, H | 1 |
Segal, D | 1 |
Horowitz, M | 1 |
Sanchez-Martinez, A | 1 |
Beavan, M | 2 |
Gegg, ME | 1 |
Whitworth, AJ | 1 |
Migdalska-Richards, A | 1 |
Daly, L | 1 |
Bezard, E | 1 |
Ishay, Y | 1 |
Szer, J | 1 |
Ilan, Y | 1 |
Arkadir, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease[NCT02941822] | Phase 2 | 23 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial[NCT05287503] | Phase 2 | 65 participants (Actual) | Interventional | 2022-02-15 | Active, not recruiting | ||
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
Genotypic Influences on Network Progression in Parkinson's Disease[NCT04228172] | 32 participants (Anticipated) | Observational | 2020-02-24 | Recruiting | |||
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy[NCT03950050] | Phase 2 | 40 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 reviews available for ambroxol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Pharmacological chaperone therapy for the treatment of inborn errors of metabolism
Topics: Ambroxol; Gaucher Disease; Humans; Mutation; Parkinson Disease | 2022 |
Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Drug Discovery; Expectorants; Gaucher Disease; Glucosyl | 2018 |
2 trials available for ambroxol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Topics: Aged; Ambroxol; Glucosylceramidase; Humans; Male; Middle Aged; Mutation; Parkinson Disease; Treatmen | 2020 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D | 2019 |
12 other studies available for ambroxol and Idiopathic Parkinson Disease
Article | Year |
---|---|
Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Topics: alpha-Synuclein; Ambroxol; Cathepsin D; Cells, Cultured; Cholinergic Agents; Glucosylceramidase; Hum | 2022 |
Generation of wild-type rat Glucocerebrosidase homology modeling: Identification of putative interactions site and mechanism for chaperone using combined in-silico and in-vitro studies.
Topics: Ambroxol; Animals; Catalytic Domain; Glucosylceramidase; Molecular Dynamics Simulation; Parkinson Di | 2022 |
Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
Topics: Ambroxol; Glucosylceramidase; Humans; Mutation; Parkinson Disease; Precision Medicine | 2020 |
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Topics: Adolescent; Adult; Aged; Ambroxol; Biological Availability; Blood-Brain Barrier; Child; Child, Presc | 2021 |
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Enzyme Inhibitors; Female; Gaucher Diseas | 2021 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Cells, Cultured; Female; Fibroblasts; Gaucher Disease; Gen | 2014 |
Magic shotgun for Parkinson's disease?
Topics: alpha-Synuclein; Ambroxol; Female; Fibroblasts; Gaucher Disease; Glucosylceramidase; Humans; Male; M | 2014 |
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Topics: Aged; Ambroxol; Antiparkinson Agents; Cells, Cultured; Female; Fibroblasts; Glucosylceramidase; Huma | 2015 |
The contribution of mutant GBA to the development of Parkinson disease in Drosophila.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
Topics: Ambroxol; Animals; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmi | 2016 |
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Topics: alpha-Synuclein; Ambroxol; Animals; Brain; Disease Models, Animal; Expectorants; Gaucher Disease; Gl | 2016 |
A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Topics: Adipose Tissue; alpha-Synuclein; Ambroxol; Animals; Autophagy; Cell Differentiation; Dopaminergic Ne | 2017 |